LYON, FRANCE
French authorities have reported the first documented human infection with Shamonda virus, an insect-borne virus previously identified in animals. The patient, who had severe immune suppression while receiving treatment for another serious illness, died in early October 2026.
Investigations are underway to determine how the infection occurred and whether the virus contributed to the patient’s death. Officials say no health risk to the general population has been identified based on current evidence.
What This First Case Means
The reported infection marks a significant development in the understanding of Shamonda virus. Before this case, the virus was known to affect animals, and no human infections had been documented.
The patient was receiving treatment at the Hospices Civils de Lyon in France. French authorities reported that the patient had severe immunodeficiency, a condition in which the immune system becomes less effective at fighting infections.
Neurological complications developed before the patient’s death. Initial investigations suggest these complications were very likely linked to the infection, although authorities are still examining the virus’s role in the patient’s overall clinical condition and death.
The European Centre for Disease Prevention and Control (ECDC) confirmed on 22 October 2026 that this was the first reported human infection. It is working with French authorities and European partners to assess the implications and investigate how the infection occurred.
The finding does not establish that Shamonda virus commonly infects humans or that it spreads easily between people.
What Is Shamonda Virus?
Shamonda virus (SHAV) is an RNA virus belonging to the Orthobunyavirus genus and the Simbu serogroup. It is genetically related to Shallenberger virus, another virus associated with livestock.
The virus was first detected in Nigeria in the 1960s and has subsequently been reported sporadically in animals in parts of Africa and Japan. Before 2026, there had been no documented human cases.
Shamonda virus was detected in European farm animals for the first time during the summer of 2026. Since then, infections have been reported in livestock across several European countries, including France, Germany, Ireland, Italy and Spain, as well as Jersey.
Cattle are among the principal animal hosts, although infections have also been identified in other animal species. The virus has attracted particular attention from veterinary researchers because of its effects on livestock health and milk production.
How Does Shamonda Virus Spread?
Shamonda virus typically spreads between animals through the bites of infected Culicoides midges. These tiny, blood-feeding insects can transmit certain viruses between susceptible animals.
In the French human case, the leading hypothesis is that the patient acquired the infection through a midge bite in eastern France, where the virus had circulated among animals during spring and summer 2026.
However, the precise transmission route has not been confirmed, and investigators have not identified the specific midge species involved.
This distinction matters because infection associated with an insect bite does not establish direct transmission through contact between an infected animal and a human. It also does not demonstrate that the virus can spread through ordinary human contact.
As of the latest ECDC update, there is only one reported human case. Available evidence has not established sustained person-to-person transmission.
What Symptoms Have Been Reported?
Scientists have very limited information about the symptoms Shamonda virus may cause in humans because this is the first documented human infection.
In the reported case, neurological complications occurred before the patient’s death. French authorities consider a link between these complications and the virus likely, but further investigations are needed to clarify the clinical findings.
Researchers cannot yet establish a typical human symptom profile, incubation period, disease severity or recovery rate.
In animals, particularly cattle, reported clinical signs include:
- Sudden fever
- Watery or loose diarrhea
- Lethargy and weakness
- Reduced appetite
- Reduced milk production
- Muscle twitching
Veterinary researchers have also investigated possible reproductive effects in infected pregnant cattle, including abortions and congenital abnormalities in calves. These findings concern animal health and should not be interpreted as established effects of Shamonda virus in humans.
More clinical evidence will be needed before scientists can determine whether human infections typically produce neurological symptoms or other forms of illness.
What Experts Say About Risk
In its report on the case, The Standard highlighted expert assessments that the discovery is scientifically important but does not, by itself, demonstrate a threat to the wider population.
Dr Ben Brennan, a group leader and senior lecturer at the MRC-University of Glasgow Centre for Virus Research, emphasised the need to interpret the discovery in context. A single infection in a severely immunocompromised patient cannot establish how the virus would affect otherwise healthy people.
Professor Paul Hunter of the University of East Anglia also noted that earlier human infections cannot be ruled out with certainty. In places where the virus has circulated among animals for decades, an earlier human infection may not necessarily have been recognized or documented.
The possibility of onward transmission appears very low based on current information, but researchers must continue investigating rather than assume the risk is absolutely zero.
French authorities have stated that no health risk to the general population has been identified at this time. This assessment reflects the evidence currently available and may be refined as further findings emerge.
What Is Known About Transmission?
Three points are especially important when interpreting this case.
First, this is a documented human infection. It establishes that Shamonda virus was detected in a person for the first time in the available scientific and public health record.
Second, the suspected route is vector-borne transmission. Authorities believe a bite from an infected midge may have transmitted the virus, but the investigation has not conclusively established how the infection occurred.
Third, human-to-human transmission has not been established. The reported case does not demonstrate that the virus spreads through everyday contact, and there is currently no evidence of sustained transmission between people.
The available reporting also does not identify eating meat or drinking milk as a known route of infection. Animal health and food safety authorities continue to follow developments as part of the wider investigation.
These distinctions help prevent the first human case from being misrepresented as proof of a widespread outbreak among people.
What Happens Next?
The ECDC is coordinating with French authorities and European partners to assess the case and improve the ability to detect any additional human infections.
Authorities are continuing clinical, laboratory and epidemiological investigations. These include examining the patient’s medical history, reviewing potential exposure to infected midges and determining whether further cases may have occurred.
The investigation also follows the One Health approach, which recognises the links between human health, animal health and the environment. Monitoring infections in livestock and tracking the insects that transmit the virus can help researchers understand potential exposure pathways.
The World Health Organization and ECDC have been notified of the case. Further findings may clarify the virus’s capacity to infect humans and whether particular groups face greater risks.
For now, the evidence does not support describing Shamonda virus as a widespread human health threat. The first documented infection is an important scientific finding, but conclusions about its wider significance must await further investigation.
The key takeaway is that Shamonda virus has been documented in a human for the first time, but its transmission route and role in the patient’s death remain under investigation. Current evidence has not identified a health risk to the general population or established sustained human-to-human transmission.
